<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The influence of sex on the development of <z:hpo ids='HP_0001513'>obesity</z:hpo>, Type 2 <z:hpo ids='HP_0000819'>Diabetes Mellitus</z:hpo> (T2DM), and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> is well documented, although the molecular mechanism underlying those differences reminds elusive </plain></SENT>
<SENT sid="1" pm="."><plain>Ligands of peroxisome proliferator-activated receptors (PPARs) are used as oral <z:chebi fb="0" ids="35526">antidiabetics</z:chebi> (PPARgamma <z:chebi fb="4" ids="48705">agonists</z:chebi>: <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>, TZDs), or for the treatment of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e>, due to their <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering properties (PPARalpha <z:chebi fb="4" ids="48705">agonists</z:chebi>: fibrates), as PPARs control transcription of a set of genes involved in the regulation of <z:chebi fb="23" ids="18059">lipid</z:chebi> and carbohydrate metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>Given a high prevalence of those <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e>, and thus a broad use of PPAR <z:chebi fb="4" ids="48705">agonists</z:chebi>, the present review will discuss distinct aspects of sex-specific differences in antiobesity treatment using those groups of PPAR ligands </plain></SENT>
</text></document>